Sage Journals: Discover world-class research

Abstract

Keywords

COVID-19 dermatology hidradenitis suppurativa acne inversa biologics TNF-α inhibitors anti-TNF-α therapy

Get full access to this article

View all access options for this article.

References

Holcomb

ZE.

Santillan

MR.

Morss-Walton

et al. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. J Am Acad Dermatol. 2020;83(4):1215-1218.doi:10.1016/j.jaad.2020.06.999

32622141

Kearns

DG.

Chat

VS.

Uppal

. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(6):e433-e434.doi:10.1016/j.jaad.2020.07.086

32735966

van der Zee

HH.

de Ruiter

van den Broecke

DG.

Dik

WA.

Laman

JD.

Prens

. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.doi:10.1111/j.1365-2133.2011.10254.x

21332464

Seltzer

JA.

Okeke

CAV.

Perry

JD.

Shipman

WD.

Okoye

GA.

Byrd

. Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83(2):e153-e154.doi:10.1016/j.jaad.2020.05.012

32389715

Robinson

PC.

Richards

Tanner

HL.

Feldmann

. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2(11):e653-e655.doi:10.1016/S2665-9913(20)30309-X

33521660

Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic

Abstract

Keywords

Get full access to this article

References